PUBLISHER: Renub Research | PRODUCT CODE: 1452708
PUBLISHER: Renub Research | PRODUCT CODE: 1452708
Epilepsy Drugs Market, Size, Global Forecast 2024-2030, Industry Trends, Share, Growth, Insight, Impact of Inflation, Top Companies Analysis
Global Epilepsy Drugs Market is envisioned to reach US$ 10.28 Billion by 2030, according to Renub Research. Globally, health systems struggle to provide critical medical offerings and ensure access to remedies for chronic conditions like epilepsy. Characterized by recurrent seizures, epilepsy entails unexpected, transient modifications in brain function, leading to convulsions, loss of recognition, or uncommon sensations and behaviors. Despite being diagnosed as a public fitness priority by the World Health Organization, epilepsy frequently lacks good enough interest and support. So, epilepsy drugs are prescribed to manage seizures by stabilizing brain electrical activity, helping sufferers manage their condition.
Global epilepsy drugs market is projected to expand at a CAGR of 4.37% from 2024 to 2030
As the world's population grows and grows old, the prevalence of epilepsy is anticipated to increase due to an expanding market. People elderly 65 and above have a higher incidence rate of epilepsy. According to the Centers for Disease Control and Prevention (CDC) record of 2023, epilepsy is one of the most common neurological issues worldwide, affecting over 1% of Americans. Furthermore, the World Health Organization reports that epilepsy affects about 50 million people globally, surpassing the number of people with cerebral palsy, multiple sclerosis, and Parkinson's disease combined.
Second-generation epilepsy drugs dominate the global epilepsy drug market. This is because of advanced efficacy, tolerability, simpler dosing, decreased danger of interactions, and improved seizure control. However, third-generation drugs have received prominence for advanced efficacy, protection, and tailored treatment. A study by Science Direct indicates a notable rise in the prescription frequency of third-generation anti-seizure medication (ASMs), increasing from 59.3% to 84.2%. This surge coincided with a decline in the frequency of first- and second-generation ASMs, dropping from 5.4% to 2.1% and 34.9% to 12.6%, respectively. Tailored to specific seizure types, these drugs feature once-daily dosing and fewer interactions, making them more appealing to patients and providers and driving increased market prominence. Hence, the global epilepsy drugs market reached US$ 7.62 Billion in 2023.
Moreover, authorities' approvals for new drugs power market growth, spurred by elevated recognition and diagnosis rates. Organizations like the Epilepsy Foundation, Epilepsy Society, Epilepsy Association of Western and Central PA, and Narayana Health promote education and attention. This has multiplied the patient pool, prompting pharmaceutical agencies to spend money on R&D, introducing novel drugs with advanced efficacy, fewer side effects, and affordability, consequently increasing remedy alternatives and market growth. For instance, Angelini Pharma announced a USD 505.5 million investment in JCR Pharmaceuticals Co., Ltd. for a brand-new epilepsy treatment in May 2023.
Also, technological improvements in diagnostics and monitoring gadgets enhance epilepsy detection and management, driving the epilepsy drugs market. For example, National Institutes of Health (NIH)-funded researchers utilized A.I. to locate mouse behavioral "fingerprints," aiding early identity without expecting seizures, requiring only one hour of video recording. Published in Neuron, the study highlights progressed 3-D video evaluation over traditional human observation-based techniques for epilepsy research.
The third generation of epilepsy drugs may seriously impact the global market
Based on the drug category, the global epilepsy drugs market is fragmented into First-Generation Drugs, Second-Generation Drugs, and Third-Generation Drugs. The third-generation class may develop significantly in the global epilepsy drugs market. Enhanced efficacy, protection, and tailor-made remedy alternatives drive accelerated adoption, making it a distinguished and increasing section in addressing neurological situations.
Focal seizures have the potential to constitute a significant portion of the global market for epilepsy drugs
The global epilepsy drugs market is segmented by seizure types into Focal Seizures, Generalized Seizures, and Non-Epileptic Seizures. Focal seizures may represent a considerable segment of the worldwide epilepsy drugs market due to their incidence and the desire for powerful treatment alternatives to control signs and symptoms and improve the effects on the affected person.
Drug shops and retail pharmacies could be expected to retain a substantial portion of the global epilepsy drugs market
The global epilepsy drugs market is categorized by distribution channels into hospital pharmacies, drug stores, retail pharmacies, and online providers. Drug shops and retail pharmacies may be predicted to keep a considerable proportion of the market. This is owed to their accessibility, which provides handy access to medicines for people with epilepsy.
Asia Pacific region is expected to witness one of the highest growth rates in the global market for epilepsy drugs
By countries, the global epilepsy drugs market is divided into North America (United States, Canada), Europe (France, Germany, Italy, Spain, United Kingdom, Belgium, Netherlands, Turkey), Asia Pacific (China, Japan, India, Australia, South Korea, Thailand, Malaysia, Indonesia, New Zealand), Latin America (Brazil, Mexico, Argentina), Middle East & Africa (South Africa, Saudi Arabia, United Arab Emirates), and Rest of the World. The Asia Pacific region is anticipated to experience one of the highest increases in the global epilepsy drugs market. This is because of favorable government initiatives, including the Intersectoral Global Action Plan on Epilepsy, the Global Campaign Against Epilepsy, and the launch of recent-generation anti-epileptic drugs. Besides, patient cognizance of powerful epilepsy drugs and the high unmet medical desires in the rising economies of India and China are propelling the epilepsy drugs market boom in the surroundings.
Key Players
Eisai Co., Ltd., UCB Inc., H. Lundbeck A/S, G.W. Pharmaceuticals Plc., Abbott Laboratories, Alkem Laboratories Limited, Bausch Health Companies Inc., GSK plc, Novartis AG., and Pfizer Inc. are the businesses in the global epilepsy drugs market.
- In January 2022 - UCB acquired Zogenix for $1.9B to expand its epilepsy product portfolio with Fintepla, a treatment for seizures associated with Dravet syndrome, a rare type of epilepsy in children.
Drug Category - Global Epilepsy Drugs Market breakup in 4 viewpoints:
1. First Generation Drugs
2. Second Generation Drugs
3. Third Generation Drugs
Seizure Types - Global Epilepsy Drugs Market breakup in 3 viewpoints:
1. Focal Seizures
2. Generalized Seizures
3. Non-Epileptic Seizures
Distribution Channel - Global Epilepsy Drugs Market breakup in 3 viewpoints:
1. Hospital Pharmacies
2. Drug Stores and Retail Pharmacies
3. Online Providers
Countries - Global Epilepsy Drugs Market breakup in 26 viewpoints:
1. North America
- 1.1 United States
- 1.2 Canada
2. Europe
- 2.1 France
- 2.2 Germany
- 2.3 Italy
- 2.4 Spain
- 2.5 United Kingdom
- 2.6 Belgium
- 2.7 Netherland
- 2.8 Turkey
3. Asia Pacific
- 3.1 China
- 3.2 Japan
- 3.3 India
- 3.4 South Korea
- 3.5 Thailand
- 3.6 Malaysia
- 3.7 Indonesia
- 3.8 Australia
- 3.9 New Zealand
4. Latin America
- 4.1 Brazil
- 4.2 Mexico
- 4.3 Argentina
5. Middle East & Africa
- 5.1 Saudi Arabia
- 5.2 UAE
- 5.3 South Africa
6. Rest of the World
All the Key players have been covered from 3 Viewpoints:
- Overview
- Recent Development
- Revenue Analysis
Company Analysis:
1. Eisai Co., Ltd.
2. UCB Inc.
3. H. Lundbeck A/S
4. GW Pharmaceuticals Plc.
5. Abbott Laboratories
6. Alkem Laboratories Limited
7. Bausch Health Companies Inc.
8. GSK plc
9. Novartis AG.
10. Pfizer Inc.
Table of Contents
1. Introduction
2. Research Methodology
3. Executive Summary
4. Market Dynamics
- 4.1 Growth Drivers
- 4.2 Challenges
5. Exploring the Disease - Background and Key Insights
- 5.1 Introduction
- 5.2 Causes
- 5.3 Classification of Epilepsies
- 5.3.1 West Syndrome
- 5.3.2 Dravet syndrome
- 5.3.3 Lennox-Gastaut syndrome
- 5.3.4 Landau-Kleffner syndrome
- 5.3.5 Epilepsy with continuous spike-and-waves during slow-wave sleep (ECSWS)
- 5.3.6 CDKL5 deficiency disorder (CDD)
- 5.4 Risk Factors
- 5.5 Pathophysiology
- 5.6 Diagnosis
- 5.6.1 Diagnostic Guidelines
- 5.6.1.1 NICE: Epilepsies in Children, Young People, and Adults (2022)
- 5.6.1.2 American Family Physician: Diagnostic Evaluation (2017)
- 5.6.1.3 The French National Authority for Health (HAS): 2020
- 5.6.1.4 German Society for Neurology (DGN) Guidelines: Diagnostics and Therapy in Neurology (2023)
- 5.6.1 Diagnostic Guidelines
- 5.7 Treatment
- 5.7.1 Antiepileptic Medications (AEDs)
- 5.7.2 Receptor Blockers
- 5.7.3 Others
- 5.7.4 Diet Therapy
- 5.7.5 Surgery
- 5.7.5.1 Phase I Evaluation (Noninvasive Tests)
- 5.7.5.2 Phase II Evaluation (Invasive Mon)
- 5.7.6 Treatment Algorithm for Medical Condition
- 5.7.7 Treatment Guidelines
- 5.7.7.1 American Epilepsy Society
- 5.7.7.2 American Family Physician - Epilepsy Treatment Options (2017)
- 5.7.7.3 The International League against Epilepsy (ILAE) Epilepsy Guidelines
- 5.7.7.4 NICE Guidelines: (2022)
- 5.7.8 Living and Coping with Epilepsy
6. Global Epilepsy Drugs Market
7. Market Share - Global Epilepsy Drugs Market
- 7.1 By Drugs Category
- 7.2 By Seizure types
- 7.3 By Distribution Channels
- 7.4 By Countries
8. Drugs Category - Global Epilepsy Drugs Market
- 8.1 First Generation Drugs
- 8.2 Second Generation Drugs
- 8.3 Third Generation Drugs
9. Seizure Types - Global Epilepsy Drugs Market
- 9.1 Focal Seizures
- 9.2 Generalized Seizures
- 9.3 Non-Epileptic Seizures
10. Distribution Channels - Global Epilepsy Drugs Market
- 10.1 Hospital Pharmacies
- 10.2 Drug Stores and Retail Pharmacies
- 10.3 Online Providers
11. Countries - Global Epilepsy Drugs Market
- 11.1 North America
- 11.1.1 United States
- 11.1.2 Canada
- 11.2 Europe
- 11.2.1 France
- 11.2.2 Germany
- 11.2.3 Italy
- 11.2.4 Spain
- 11.2.5 United Kingdom
- 11.2.6 Belgium
- 11.2.7 Netherland
- 11.2.8 Turkey
- 11.3 Asia Pacific
- 11.3.1 China
- 11.3.2 Japan
- 11.3.3 India
- 11.3.4 South Korea
- 11.3.5 Thailand
- 11.3.6 Malaysia
- 11.3.7 Indonesia
- 11.3.8 Australia
- 11.3.9 New Zealand
- 11.4 Latin America
- 11.4.1 Brazil
- 11.4.2 Mexico
- 11.4.3 Argentina
- 11.5 Middle East & Africa
- 11.5.1 Saudi Arabia
- 11.5.2 UAE
- 11.5.3 South Africa
- 11.6 Rest of the World
12. Porter's Five Forces Analysis - Global Epilepsy Drugs Market
- 12.1 Bargaining Power of Buyers
- 12.2 Bargaining Power of Suppliers
- 12.3 Degree of Rivalry
- 12.4 Threat of New Entrants
- 12.5 Threat of Substitutes
13. SWOT Analysis - Global Epilepsy Drugs Market
- 13.1 Strength
- 13.2 Weakness
- 13.3 Opportunity
- 13.4 Threat
14. Analysis of Marketed Medications/Drugs
- 14.1 Key Players
- 14.2 EPIDIOLEX/EPIDYOLEX (cannabidiol) - Jazz Pharmaceuticals
- 14.2.1 Description of Drugs
- 14.2.2 Regulatory Milestones
- 14.2.3 Clinical Development Process
- 14.2.4 Safety and Efficacy
- 14.3 XCOPRI/ONTOZRY(cenobamate) - SK Biopharmaceutical/ Pharma/Ono Pharmaceutical
- 14.3.1 Description of Drugs
- 14.3.2 Regulatory Milestones
- 14.3.3 Clinical Development Process
- 14.3.4 Safety and Efficacy
- 14.4 FINTEPLA (fenfluramine) - UCB/Nippon Shinyaku
- 14.4.1 Description of Drugs
- 14.4.2 Regulatory Milestones
- 14.4.3 Clinical Development Process
- 14.4.4 Safety and Efficacy
- 14.5 NAYZILAM (midazolam) nasal spray - UCB Pharma
- 14.5.1 Description of Drugs
- 14.5.2 Regulatory Milestones
- 14.5.3 Clinical Development Process
- 14.5.4 Safety and Efficacy
- 14.6 VALTOCO (diazepam nasal spray) - Neurelis/Aculys Pharma
- 14.6.1 Description of Drugs
- 14.6.2 Regulatory Milestones
- 14.6.3 Clinical Development Process
- 14.6.4 Safety and Efficacy
- 14.7 ZTALMY (ganaxolone) - Marinus Pharmaceuticals/Ovid Therapeutics/Orion
- 14.7.1 Description of Drugs
- 14.7.2 Regulatory Milestones
- 14.7.3 Clinical Development Process
- 14.7.4 Safety and Efficacy
- 14.8 BRIVIACT/NUBRIVEO (brivaracetam) - UCB Pharma
- 14.8.1 Description of Drugs
- 14.8.2 Regulatory Milestones
- 14.8.3 Clinical Development Process
- 14.8.4 Safety and Efficacy
- 14.9 FYCOMPA (perampanel) - Eisai/Catalyst Pharmaceutical
- 14.9.1 Description of Drugs
- 14.9.2 Regulatory Milestones
- 14.9.3 Clinical Development Process
- 14.9.4 Safety and Efficacy
- 14.10 OXTELLAR XR (oxcarbazepine) - Supernus Pharmaceuticals
- 14.10.1 Description of Drugs
- 14.10.2 Regulatory Milestones
- 14.10.3 Clinical Development Process
- 14.10.4 Safety and Efficacy
- 14.11 VIMPAT (lacosamide) - UCB Pharma/Daiichi Sankyo
- 14.11.1 Description of Drugs
- 14.11.2 Regulatory Milestones
- 14.11.3 Clinical Development Process
- 14.11.4 Safety and Efficacy
15. Analysis of Emerging Drugs
- 15.1 Key Cross Competition
- 15.2 XEN1101 - Xenon Pharmaceuticals
- 15.2.1 Description of Drug
- 15.2.2 Clinical Research & Development
- 15.2.3 Safety and efficacy
- 15.3 LIBERVANT (diazepam buccal film) - Aquestive Therapeutics/Atnahs Pharma (Pharmanovia)
- 15.3.1 Description of Drug
- 15.3.2 Clinical Research & Development
- 15.3.3 Safety and efficacy
- 15.4 Soticlestat (TAK-935) - Takeda/Ovid Therapeutics
- 15.4.1 Description of Drug
- 15.4.2 Clinical Research & Development
- 15.4.3 Safety and efficacy
- 15.5 COMFYDE (carisbamate) - SK Biopharmaceuticals (SK Life Science)
- 15.5.1 Description of Drug
- 15.5.2 Clinical Research & Development
- 15.5.3 Safety and efficacy
- 15.6 BHV-7000 (KB-3061) - Biohaven Pharmaceuticals/Knopp Biosciences
- 15.6.1 Description of Drug
- 15.6.2 Clinical Research & Development
- 15.6.3 Safety and efficacy
- 15.7 STACCATO alprazolam (benzodiazepine) - UCB Pharma/Alexza Pharmaceuticals
- 15.7.1 Description of Drug
- 15.7.2 Clinical Research & Development
- 15.7.3 Safety and efficacy
- 15.8 NBI-827104 (ACT-709478) - Neurocrine Biosciences/Idorsia Pharmaceuticals
- 15.8.1 Description of Drug
- 15.8.2 Clinical Research & Development
- 15.8.3 Safety and efficacy
- 15.9 Ivermectin (EQU-001) - Equilibre Biopharmaceuticals
- 15.9.1 Description of Drug
- 15.9.2 Clinical Research & Development
- 15.9.3 Safety and efficacy
16. Regulations and Reimbursement Policies
17. Key Players Analysis
- 17.1 Eisai Co., Ltd.
- 17.1.1 Overview
- 17.1.2 Recent Development
- 17.1.3 Revenue Analysis
- 17.2 UCB Inc.
- 17.2.1 Overview
- 17.2.2 Recent Development
- 17.2.3 Revenue Analysis
- 17.3 H. Lundbeck A/S
- 17.3.1 Overview
- 17.3.2 Recent Development
- 17.3.3 Revenue Analysis
- 17.4 GW Pharmaceuticals Plc.
- 17.4.1 Overview
- 17.4.2 Recent Development
- 17.4.3 Revenue Analysis
- 17.5 Abbott Laboratories
- 17.5.1 Overview
- 17.5.2 Recent Development
- 17.5.3 Revenue Analysis
- 17.6 Alkem Laboratories Limited
- 17.6.1 Overview
- 17.6.2 Recent Development
- 17.6.3 Revenue Analysis
- 17.7 Bausch Health Companies Inc.
- 17.7.1 Overview
- 17.7.2 Recent Development
- 17.7.3 Revenue Analysis
- 17.8 GSK plc
- 17.8.1 Overview
- 17.8.2 Recent Development
- 17.8.3 Revenue Analysis
- 17.9 Novartis AG
- 17.9.1 Overview
- 17.9.2 Recent Development
- 17.9.3 Revenue Analysis
- 17.10 Pfizer Inc
- 17.10.1 Overview
- 17.10.2 Recent Development
- 17.10.3 Revenue Analysis
List of Figures
- Figure-01: Global - Epilepsy Drugs Market (Billion US$), 2019 - 2023
- Figure-02: Global - Forecast for Epilepsy Drugs Market (Billion US$), 2024 - 2030
- Figure-03: Drugs Category - First Generation Drugs Market (Million US$), 2019 - 2023
- Figure-04: Drugs Category - Forecast for First Generation Drugs Market (Million US$), 2024 - 2030
- Figure-05: Drugs Category - Second Generation Drugs Market (Million US$), 2019 - 2023
- Figure-06: Drugs Category - Forecast for Second Generation Drugs Market (Million US$), 2024 - 2030
- Figure-07: Drugs Category - Third Generation Drugs Market (Million US$), 2019 - 2023
- Figure-08: Drugs Category - Forecast for Third Generation Drugs Market (Million US$), 2024 - 2030
- Figure-09: Seizure Types - Focal Seizures Market (Million US$), 2019 - 2023
- Figure-10: Seizure Types - Forecast for Focal Seizures Market (Million US$), 2024 - 2030
- Figure-11: Seizure Types - Generalized Seizures Market (Million US$), 2019 - 2023
- Figure-12: Seizure Types - Forecast for Generalized Seizures Market (Million US$), 2024 - 2030
- Figure-13: Seizure Types - Non-Epileptic Seizures Market (Million US$), 2019 - 2023
- Figure-14: Seizure Types - Forecast for Non-Epileptic Seizures Market (Million US$), 2024 - 2030
- Figure-15: Distribution Channels - Hospital Pharmacies Market (Million US$), 2019 - 2023
- Figure-16: Distribution Channels - Forecast for Hospital Pharmacies Market (Million US$), 2024 - 2030
- Figure-17: Distribution Channels - Drug Stores and Retail Pharmacies Market (Million US$), 2019 - 2023
- Figure-18: Distribution Channels - Forecast for Drug Stores and Retail Pharmacies Market (Million US$), 2024 - 2030
- Figure-19: Distribution Channels - Online Providers Market (Million US$), 2019 - 2023
- Figure-20: Distribution Channels - Forecast for Online Providers Market (Million US$), 2024 - 2030
- Figure-21: United States - Epilepsy Drugs Market (Million US$), 2019 - 2023
- Figure-22: United States - Forecast for Epilepsy Drugs Market (Million US$), 2024 - 2030
- Figure-23: Canada - Epilepsy Drugs Market (Million US$), 2019 - 2023
- Figure-24: Canada - Forecast for Epilepsy Drugs Market (Million US$), 2024 - 2030
- Figure-25: France - Epilepsy Drugs Market (Million US$), 2019 - 2023
- Figure-26: France - Forecast for Epilepsy Drugs Market (Million US$), 2024 - 2030
- Figure-27: Germany - Epilepsy Drugs Market (Million US$), 2019 - 2023
- Figure-28: Germany - Forecast for Epilepsy Drugs Market (Million US$), 2024 - 2030
- Figure-29: Italy - Epilepsy Drugs Market (Million US$), 2019 - 2023
- Figure-30: Italy - Forecast for Epilepsy Drugs Market (Million US$), 2024 - 2030
- Figure-31: Spain - Epilepsy Drugs Market (Million US$), 2019 - 2023
- Figure-32: Spain - Forecast for Epilepsy Drugs Market (Million US$), 2024 - 2030
- Figure-33: United Kingdom - Epilepsy Drugs Market (Million US$), 2019 - 2023
- Figure-34: United Kingdom - Forecast for Epilepsy Drugs Market (Million US$), 2024 - 2030
- Figure-35: Belgium - Epilepsy Drugs Market (Million US$), 2019 - 2023
- Figure-36: Belgium - Forecast for Epilepsy Drugs Market (Million US$), 2024 - 2030
- Figure-37: Netherland - Epilepsy Drugs Market (Million US$), 2019 - 2023
- Figure-38: Netherland - Forecast for Epilepsy Drugs Market (Million US$), 2024 - 2030
- Figure-39: Turkey - Epilepsy Drugs Market (Million US$), 2019 - 2023
- Figure-40: Turkey - Forecast for Epilepsy Drugs Market (Million US$), 2024 - 2030
- Figure-41: China - Epilepsy Drugs Market (Million US$), 2019 - 2023
- Figure-42: China - Forecast for Epilepsy Drugs Market (Million US$), 2024 - 2030
- Figure-43: Japan - Epilepsy Drugs Market (Million US$), 2019 - 2023
- Figure-44: Japan - Forecast for Epilepsy Drugs Market (Million US$), 2024 - 2030
- Figure-45: India - Epilepsy Drugs Market (Million US$), 2019 - 2023
- Figure-46: India - Forecast for Epilepsy Drugs Market (Million US$), 2024 - 2030
- Figure-47: South Korea - Epilepsy Drugs Market (Million US$), 2019 - 2023
- Figure-48: South Korea - Forecast for Epilepsy Drugs Market (Million US$), 2024 - 2030
- Figure-49: Thailand - Epilepsy Drugs Market (Million US$), 2019 - 2023
- Figure-50: Thailand - Forecast for Epilepsy Drugs Market (Million US$), 2024 - 2030
- Figure-51: Malaysia - Epilepsy Drugs Market (Million US$), 2019 - 2023
- Figure-52: Malaysia - Forecast for Epilepsy Drugs Market (Million US$), 2024 - 2030
- Figure-53: Indonesia - Epilepsy Drugs Market (Million US$), 2019 - 2023
- Figure-54: Indonesia - Forecast for Epilepsy Drugs Market (Million US$), 2024 - 2030
- Figure-55: Australia - Epilepsy Drugs Market (Million US$), 2019 - 2023
- Figure-56: Australia - Forecast for Epilepsy Drugs Market (Million US$), 2024 - 2030
- Figure-57: New Zealand - Epilepsy Drugs Market (Million US$), 2019 - 2023
- Figure-58: New Zealand - Forecast for Epilepsy Drugs Market (Million US$), 2024 - 2030
- Figure-59: Brazil - Epilepsy Drugs Market (Million US$), 2019 - 2023
- Figure-60: Brazil - Forecast for Epilepsy Drugs Market (Million US$), 2024 - 2030
- Figure-61: Mexico - Epilepsy Drugs Market (Million US$), 2019 - 2023
- Figure-62: Mexico - Forecast for Epilepsy Drugs Market (Million US$), 2024 - 2030
- Figure-63: Argentina - Epilepsy Drugs Market (Million US$), 2019 - 2023
- Figure-64: Argentina - Forecast for Epilepsy Drugs Market (Million US$), 2024 - 2030
- Figure-65: Saudi Arabia - Epilepsy Drugs Market (Million US$), 2019 - 2023
- Figure-66: Saudi Arabia - Forecast for Epilepsy Drugs Market (Million US$), 2024 - 2030
- Figure-67: UAE - Epilepsy Drugs Market (Million US$), 2019 - 2023
- Figure-68: UAE - Forecast for Epilepsy Drugs Market (Million US$), 2024 - 2030
- Figure-69: South Africa - Epilepsy Drugs Market (Million US$), 2019 - 2023
- Figure-70: South Africa - Forecast for Epilepsy Drugs Market (Million US$), 2024 - 2030
- Figure-71: Rest of the World - Epilepsy Drugs Market (Million US$), 2019 - 2023
- Figure-72: Rest of the World - Forecast for Epilepsy Drugs Market (Million US$), 2024 - 2030
- Figure-73: Eisai Co., Ltd. - Global Revenue (Million US$), 2019 - 2023
- Figure-74: Eisai Co., Ltd. - Forecast for Global Revenue (Million US$), 2024 - 2030
- Figure-75: UCB Inc. - Global Revenue (Million US$), 2019 - 2023
- Figure-76: UCB Inc. - Forecast for Global Revenue (Million US$), 2024 - 2030
- Figure-77: H. Lundbeck A/S - Global Revenue (Million US$), 2019 - 2023
- Figure-78: H. Lundbeck A/S - Forecast for Global Revenue (Million US$), 2024 - 2030
- Figure-79: GW Pharmaceuticals Plc. - Global Revenue (Million US$), 2019 - 2023
- Figure-80: GW Pharmaceuticals Plc. - Forecast for Global Revenue (Million US$), 2024 - 2030
- Figure-81: Abbott Laboratories - Global Revenue (Million US$), 2019 - 2023
- Figure-82: Abbott Laboratories - Forecast for Global Revenue (Million US$), 2024 - 2030
- Figure-83: Alkem Laboratories Limited - Global Revenue (Million US$), 2019 - 2023
- Figure-84: Alkem Laboratories Limited - Forecast for Global Revenue (Million US$), 2024 - 2030
- Figure-85: Bausch Health Companies Inc. - Global Revenue (Million US$), 2019 - 2023
- Figure-86: Bausch Health Companies Inc. - Forecast for Global Revenue (Million US$), 2024 - 2030
- Figure-87: GSK plc - Global Revenue (Million US$), 2019 - 2023
- Figure-88: GSK plc - Forecast for Global Revenue (Million US$), 2024 - 2030
- Figure-89: Novartis AG - Global Revenue (Million US$), 2019 - 2023
- Figure-90: Novartis AG - Forecast for Global Revenue (Million US$), 2024 - 2030
- Figure-91: Pfizer Inc - Global Revenue (Million US$), 2019 - 2023
- Figure-92: Pfizer Inc - Forecast for Global Revenue (Million US$), 2024 - 2030
List of Tables
- Table-01: Global - Epilepsy Drugs Market Share by Drugs Category (Percent), 2019 - 2023
- Table-02: Global - Forecast for Global Epilepsy Drugs Market Share by Drugs Category (Percent), 2024 - 2030
- Table-03: Global - Epilepsy Drugs Market Share by Seizure Type (Percent), 2019 - 2023
- Table-04: Global - Forecast for Global Epilepsy Drugs Market Share by Seizure Type (Percent), 2024 - 2030
- Table-05: Global - Epilepsy Drugs Market Share by Distribution Channels (Percent), 2019 - 2023
- Table-06: Global - Forecast for Global Epilepsy Drugs Market Share by Distribution Channels (Percent), 2024 - 2030
- Table-07: Global - Epilepsy Drugs Market Share by Countries (Percent), 2019 - 2023
- Table-08: Global - Forecast for Global Epilepsy Drugs Market Share by Countries (Percent), 2024 - 2030
